Arthrosi Therapeutics Receives FDA Fast Track Designation for AR882 in Tophaceous Gout
Arthrosi Therapeutics receives FDA Fast Track Designation for AR882 in treating tophaceous gout, a serious condition affecting 2 million gout patients in the U.S. AR882, a next-generation URAT1 inhibitor, aims to address this unmet medical need.
Highlighted Terms
Related News
Arthrosi Therapeutics Receives FDA Fast Track Designation for AR882 in Tophaceous Gout
Arthrosi Therapeutics receives FDA Fast Track Designation for AR882 in treating tophaceous gout, a serious condition affecting 2 million gout patients in the U.S. AR882, a next-generation URAT1 inhibitor, aims to address this unmet medical need.